Spero Therapeutics
US-based Spero Therapeutics develops and commercializes novel treatments for MDR bacterial infections.
Founded
2013US-based Spero Therapeutics develops and commercializes novel treatments for MDR bacterial infections.
Founded in Cambridge, United States, Spero Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. The company's core mission is to advance new therapies for patients with rare orphan diseases and serious bacterial infections in both hospital and community settings. Spero Therapeutics offers a technology platform that enhances the spectrum and potency of existing antibiotics, with products like SPR720, an oral antibiotic designed to treat Nontuberculous Mycobacterial Pulmonary disease.
Spero Therapeutics has garnered attention from notable investors and industry leaders, establishing itself as a key player in the infectious disease field. The company’s innovative approach has led to significant achievements, including the development of SPR720, which has the potential to be the first approved novel oral agent for its targeted condition. Spero's impact is profound, providing hope and advanced treatment options for patients battling rare and severe bacterial infections worldwide.
Companies similar to Spero Therapeutics include Venatorx Pharmaceuticals, Summit Therapeutics, Nexcida Therapeutics and Synspira.
Spero Therapeutics was founded in 2013.
Spero Therapeutics' headquarters is located in Cambridge, MA, US.
Spero Therapeutics' most recent funding round was for $9M (USD) in September 2022.
As of Sep 22, 2022, Spero Therapeutics has disclosed funding of $443.6M (USD). Undisclosed round amounts are excluded.
Spero Therapeutics has 35 employees as of Feb 6, 2024.
Synspira
